Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long Term Clear all
Terminated No phase listed Observational

Gastric Emptying Using Two Imaging Methods for Those Who Have Undergone POSE2 Weight Loss Procedure

NCT04502732
View directory record Official record
Conditions
Weight Loss
Interventions
NSSM and GEBT
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 15, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT03814187
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions
Inclisiran Sodium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
141
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 15, 2026, 11:14 AM EDT
Completed No phase listed Observational

A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

NCT05413044
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
140,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 15, 2026, 11:14 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

NCT04086121
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 15, 2026, 11:14 AM EDT
Recruiting Phase 2 Interventional

Open-label Extension Study in Participants With Early Alzheimer's Disease

NCT07105709
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
GSK4527226
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Maitland, Florida • Miami, Florida • Stuart, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 15, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

NCT02292784
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, Atosiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Weeks to 20 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Park Ridge, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 15, 2026, 11:14 AM EDT
Completed No phase listed Observational

Long-term Lifestyle Change and Testosterone Replacement

NCT03256292
View directory record Official record
Conditions
Hypogonadism, Aging, Overweight and Obesity
Interventions
Testosterone replacement, lifestyle
Drug · Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
65 Years to 85 Years · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 15, 2026, 11:14 AM EDT
Completed Phase 2Phase 3 Interventional

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

NCT00424892
View directory record Official record
Conditions
Fibromyalgia
Interventions
Desvenlafaxine Sustained Release
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
59
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 15, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Cariprazine in Patients With Schizophrenia

NCT01104792
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
39
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Carson, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 15, 2026, 11:14 AM EDT
Completed Early Phase 1 Interventional

Determinants of Diabetes Remission After Gastric Bypass Surgery

NCT02287285
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exendin9
Drug
Lead sponsor
Blandine Laferrere
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 15, 2026, 11:14 AM EDT
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 15, 2026, 11:14 AM EDT
Terminated Phase 3 Interventional Results available

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 18 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Wichita, Kansas • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 15, 2026, 11:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Hoosier Moms Cohort

NCT03696368
View directory record Official record
Conditions
Pregnancy Related, Gestational Diabetes
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
6
States / cities
Indianapolis, Indiana • Newburgh, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 15, 2026, 11:14 AM EDT
Recruiting No phase listed Observational

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

NCT06564974
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vamorolone
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 11:14 AM EDT
Withdrawn Phase 3 Interventional

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

NCT02799758
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
NK-104-CR, Livalo® IR, Placebo (for NK-104-CR), Placebo (for Livalo® IR)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
69
States / cities
Foley, Alabama • Huntsville, Alabama • Montgomery, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 15, 2026, 11:14 AM EDT
Recruiting Phase 4 Interventional

LINQ® Procedure vs. Conventional Medical Management for Sacroiliac Dysfunction

NCT07558278
View directory record Official record
Conditions
Sacroiliac Joint Pain
Interventions
Bone Allograft, Conventional Medical Management (CMM)
Procedure · Other
Lead sponsor
PainTEQ, LLC
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Shenandoah, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 15, 2026, 11:14 AM EDT
Recruiting Phase 3 Interventional

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

NCT06689085
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Testosterone enanthate
Combination Product
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
12 Years to 17 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 15, 2026, 11:14 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

NCT02161185
View directory record Official record
Conditions
Epilepsy
Interventions
USL261
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Fresno, California • Ventura, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 15, 2026, 11:14 AM EDT
Terminated Phase 4 Interventional Results available

Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers

NCT02718625
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Santyl, SoloSite®
Biological
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lee's Summit, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 15, 2026, 11:14 AM EDT
Completed No phase listed Observational Results available

Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients

NCT01618240
View directory record Official record
Conditions
Swallowing Disorder, Aspiration, Long Term Ventilation
Interventions
Muscle Strength Measurement, Ventilator
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 15, 2026, 11:14 AM EDT
Not listed Phase 2Phase 3 Interventional

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

NCT06229665
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
Valeda Light Delivery System
Device
Lead sponsor
LumiThera, Inc.
Industry
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 15, 2026, 11:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

NCT06716606
View directory record Official record
Conditions
Connective Tissue Diseases
Interventions
Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 11:14 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

NCT03654755
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ASN002
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Anniston, Alabama • Birmingham, Alabama • Fremont, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 15, 2026, 11:14 AM EDT
Withdrawn Not applicable Interventional

Long Term Sidus PMCF

NCT04063943
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic; Arthrosis
Interventions
Sidus Stem-Free Shoulder
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Louisville, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 15, 2026, 11:14 AM EDT